Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma

Restricted access

Sentinel lymph node (SLN) biopsy has emerged over the past 2 decades as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). Large multi-institutional studies have confirmed that when performed by experienced surgeons, it is an accurate, reliable technique for identifying occult regional nodal disease, and that SLN status is the most important prognostic factor in patients with stage I and II melanoma. However, the incidence of occult regional nodal metastasis in patients with thin melanoma (≤ 1.0 mm; approximately 70% of patients with newly diagnosed melanoma) is low, and whether to perform SLN biopsy in these patients remains controversial. Several predictors of SLN metastasis in patients with thin melanoma have been suggested, but none widely accepted. This article reviews current literature on these predictors in patients with thin melanoma. Although the ability to draw conclusions was limited by the size and design of the available studies, the authors tentatively conclude that SLN biopsy can be considered for patients with melanomas 0.75 mm or larger, those with T1b melanomas (i.e., ≤ 1.0 mm; Clark level IV/V and/or ulcerated), and those with thin melanomas with an increased tumor mitotic rate (especially ≥ 1 mitosis/mm2). Including younger age (e.g., ≤ 40 years) in the decision also seems reasonable, particularly if the primary tumor is associated with a high tumor mitotic rate. Tumor regression does not seem to be associated with an increased risk for SLN metastasis. Firm conclusions on the predictive value of vertical growth phase, absence of tumor-infiltrating lymphocytes, or male gender were not possible, particularly if used as a sole criterion for offering this procedure. SLN biopsy should be discussed with all patients with newly diagnosed thin melanoma.

Correspondence: Jeffrey E. Gershenwald, MD, Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: jgershen@mdanderson.org
  • 1

    RiesLAMelbertDKrapchoM. eds. SEER Cancer Statistics Review 1975-2005. Available at: http://seer.cancer.gov/csr/1975_2005/index.html. Accessed February 6 2009.

    • Search Google Scholar
    • Export Citation
  • 2

    JemalASiegelRWardE. Cancer statistics, 2008. CA Cancer J Clin2008;58:7196.

  • 3

    BalchCMBuzaidACSoongSJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol2001;19:36353648.

    • Search Google Scholar
    • Export Citation
  • 4

    BalchCMSoongSJGershenwaldJE. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol2001;19:36223634.

    • Search Google Scholar
    • Export Citation
  • 5

    ThompsonJFShawHM. Is sentinel lymph node biopsy appropriate in patients with thin melanomas: too early to tell?Ann Surg Oncol2006;13:279281.

    • Search Google Scholar
    • Export Citation
  • 6

    BalchCMBuzaidACAtkinsMB. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer2000;88:14841491.

  • 7

    GershenwaldJEThompsonWMansfieldPF. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol1999;17:976983.

    • Search Google Scholar
    • Export Citation
  • 8

    GershenwaldJEBalchCMThompsonJF. Intraoperative mapping and sentinel node technology in patients with melanoma. In: BalchCM ed. Cutaneous Melanoma5th ed. St. Louis: Quality Medical Publishing Inc.; in press.

    • Search Google Scholar
    • Export Citation
  • 9

    MortonDLWenDRWongJH. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg1992;127:392399.

  • 10

    ThompsonJFMcCarthyWHBoschCM. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res1995;5:255260.

    • Search Google Scholar
    • Export Citation
  • 11

    AgneseDMAbdessalamSFBurakWEJr. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery2003;134:542547; discussion 547–548.

    • Search Google Scholar
    • Export Citation
  • 12

    BedrosianIFariesMBGuerryDT. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol2000;7:262267.

    • Search Google Scholar
    • Export Citation
  • 13

    BleicherRJEssnerRFoshagLJ. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol2003;21:13261331.

  • 14

    CecchiRBuralliLInnocentiS. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol2007;34:512515.

  • 15

    CecchiRPavesiMBuralliL. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital2008;60:257260.

    • Search Google Scholar
    • Export Citation
  • 16

    HershkoDDRobbBWLowyAM. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol2006;93:279285.

  • 17

    JacobsIAChangCKDasGuptaTK. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol2003;10:558561.

    • Search Google Scholar
    • Export Citation
  • 18

    KesmodelSBKarakousisGCBotbylJD. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol2005;12:449458.

    • Search Google Scholar
    • Export Citation
  • 19

    KoskivuoISuominenENiinikoskiJ. Sentinel node metastasectomy in thin <or=1-mm melanoma. Langenbecks Arch Surg2005;390:403407.

  • 20

    KruperLLSpitzFRCzernieckiBJ. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer2006;107:24362445.

    • Search Google Scholar
    • Export Citation
  • 21

    LoweJBHurstEMoleyJF. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol2003;139:617621.

  • 22

    MorrisKTBusamKJBeroS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol2008;15:316322.

    • Search Google Scholar
    • Export Citation
  • 23

    NahabedianMYTufaroAPMansonPN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?Ann Plast Surg2003;50:601606.

  • 24

    OlahJGyulaiRKoromI. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol2003;149:662663.

    • Search Google Scholar
    • Export Citation
  • 25

    Oliveira FilhoRSFerreiraLMBiasiLJ. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res2003;36:347350.

    • Search Google Scholar
    • Export Citation
  • 26

    PuleoCAMessinaJLRikerAI. Sentinel node biopsy for thin melanomas: which patients should be considered?Cancer Control2005;12:230235.

  • 27

    RanieriJMWagnerJDWenckS. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol2006;13:927932.

  • 28

    SondakVKTaylorJMSabelMS. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol2004;11:247258.

    • Search Google Scholar
    • Export Citation
  • 29

    StitzenbergKBGrobenPASternSL. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol2004;11:900906.

    • Search Google Scholar
    • Export Citation
  • 30

    TaylorRCPatelAPanageasKS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol2007;25:869875.

    • Search Google Scholar
    • Export Citation
  • 31

    VaqueranoJKraybillWGDriscollDL. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol2006;13:198204.

    • Search Google Scholar
    • Export Citation
  • 32

    WongSLBradyMSBusamKJ. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol2006;13:302309.

  • 33

    WrightBEScheriRPYeX. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg2008;143:892899; discussion 899–900.

    • Search Google Scholar
    • Export Citation
  • 34

    EdgeSByrdDCarducciM eds. Melanoma of the skin. In: AJCC Cancer Staging Manual7th ed. New York: Springer; in press

  • 35

    CoitDGAndtbackaRBichakjianCK. NCCN Clinical practice Guidelines in Oncology: Melanoma. Version 2 2009. Available at: http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp. Accessed February 6 2009.

    • Search Google Scholar
    • Export Citation
  • 36

    BalchCMMortonDLGershenwaldJE. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatolin press

  • 37

    AJCC Cancer Staging Manual5th ed. Philadelphia: LippincottRaven Publishers; 1997.

  • 38

    ClarkWHJrElderDEGuerryDT. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst1989;81:18931904.

    • Search Google Scholar
    • Export Citation
  • 39

    GimottyPAGuerryDMingME. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol2004;22:36683676.

    • Search Google Scholar
    • Export Citation
  • 40

    SzymikBWoosleyJT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol1993;20:5053.

    • Search Google Scholar
    • Export Citation
  • 41

    BlessingKMcLarenKM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology1992;20:315322.

    • Search Google Scholar
    • Export Citation
  • 42

    SlingluffCLJrVollmerRTReintgenDS. Lethal “thin” malignant melanoma. Identifying patients at risk. Ann Surg1988;208:150161.

  • 43

    TefanyFJBarnetsonRSHallidayGM. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol1991;97:197202.

    • Search Google Scholar
    • Export Citation
  • 44

    GuitartJLoweLPiepkornM. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol2002;138:603608.

    • Search Google Scholar
    • Export Citation
  • 45

    BrogelliLRealiUMMorettiS. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res1992;2:8791.

  • 46

    KellyJWSagebielRWBloisMS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer1985;56:22872291.

    • Search Google Scholar
    • Export Citation
  • 47

    CzarnetzkiBMDenterMBrockerEB. Clinical features of superficial spreading melanomas with zones of regression. J Cancer Res Clin Oncol1984;107:225228.

    • Search Google Scholar
    • Export Citation
  • 48

    ClementeCGMihmMCJrBufalinoR. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer1996;77:13031310.

    • Search Google Scholar
    • Export Citation
  • 49

    ChaoCMartinRCIIRossMI. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol2004;11:259264.

  • 50

    RousseauDLJrRossMIJohnsonMM. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol2003;10:569574.

    • Search Google Scholar
    • Export Citation
  • 51

    ThompsonJFShawHM. Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy?Ann Surg Oncol2004;11:233235.

    • Search Google Scholar
    • Export Citation
  • 52

    GershenwaldJEThompsonJFWarnekeC. Defining indications for SLN biopsy in patients with thin melanoma—preliminary results of an international thin melanoma working group. Presented at the 6th Biennial International Sentinel Node Society Meeting; Sydney, Australia; February 18–20, 2008.

    • Search Google Scholar
    • Export Citation
  • 53

    KarakousisGCGimottyPABotbylJD. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol2006;13:533541.

  • 54

    ThompsonJFShawHM. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol2000;7:251252.

  • 55

    GershenwaldJEAndtbackaRHPrietoVG. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol2008;26:42964303.

    • Search Google Scholar
    • Export Citation
  • 56

    LeeJHEssnerRTorisu-ItakuraH. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol2004;22:36773684.

    • Search Google Scholar
    • Export Citation
  • 57

    McMastersKMWongSLEdwardsMJ. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol2002;9:137141.

  • 58

    SabelMSGriffithKSondakVK. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg2005;201:3747.

    • Search Google Scholar
    • Export Citation
  • 59

    van AkkooiACde WiltJHVerhoefC. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?Ann Oncol2006;17:15781585.

    • Search Google Scholar
    • Export Citation
  • 60

    McKinnonJGYuXQMcCarthyWH. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer2003;98:12231231.

    • Search Google Scholar
    • Export Citation
  • 61

    KarakousisGCGimottyPACzernieckiBJ. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol2007;14:15961603.

    • Search Google Scholar
    • Export Citation
  • 62

    McMastersKM. What good is sentinel lymph node biopsy for melanoma if it does not improve survival?Ann Surg Oncol2004;11:810812.

  • 63

    McMastersKMReintgenDSRossMI. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol2001;19:28512855.

    • Search Google Scholar
    • Export Citation
  • 64

    MortonDLCochranAJThompsonJF. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg2005;242:302311; discussion 311–313.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 135 135 38
PDF Downloads 70 70 8
EPUB Downloads 0 0 0